Can Finerenone Alter Glomerular Disease Trajectory? - Takeaways - MDSpire

Can Finerenone Alter Glomerular Disease Trajectory?

A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.

  • By

  • Kathryn Wighton

  • June 5, 2026

  • 4 min

Share

  • 1

    The FIND-CKD trial included 903 participants with glomerular diseases, assessing the effects of finerenone versus placebo.

  • 2

    Finerenone reduced the eGFR decline by 1.22 mL/min/1.73 m² per year after 3 months compared to placebo.

  • 3

    In the immunoglobulin A nephropathy subgroup, finerenone decreased urinary albumin-to-creatinine ratio by 47%.

  • 4

    Serious adverse events were similar between finerenone (20%) and placebo (21%) groups, with low rates of hyperkalemia.

  • 5

    The study faced limitations, including reliance on investigator-reported diagnoses and lack of biopsy confirmation for many participants.

Original Source(s)

Can Finerenone Alter Glomerular Disease Trajectory?

  • by Kathryn Wighton

  • June 5, 2026

Related Content

CGM Linked to More Time in Range

In a randomized crossover trial of insulin-treated patients receiving hemodialysis, real-time continuous glucose monitoring did not improve the primary hypoglycemia outcome but increased time in range and reduced time above range vs capillary testing.

Mavacamten Treatment Associated With Improved Diastolic Function, Remodeling Markers

Real-world follow-up data from 465 patients add to evidence from earlier randomized trials.

Early Nephrology Consultation and Acute Kidney Injury in Hospitalized Patients: A Randomized Clinical Trial